A Phase I, Open-Label Study to Assess the Pharmacokinetics and Safety of Atezolizumab Administered Intravenously as a Single Agent or in Combination With Chemotherapy to Chinese Patients With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2018
At a glance
- Drugs Atezolizumab (Primary) ; Cisplatin; Gemcitabine
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms IMYO29233
- Sponsors Roche
- 11 Jun 2018 Planned End Date changed from 10 Jul 2020 to 10 Jan 2020.
- 11 Jun 2018 Planned primary completion date changed from 28 May 2018 to 8 Mar 2019.
- 30 Aug 2017 Planned End Date changed from 28 May 2018 to 10 Jul 2020.